Genomic Research Capacity Building for Cryptococcosis Translational Studies
隐球菌病转化研究的基因组研究能力建设
基本信息
- 批准号:10653960
- 负责人:
- 金额:$ 55.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS-Related Opportunistic InfectionsAcquired Immunodeficiency SyndromeAcuteAdultAffectAfricaAfricanAllelesBasic ScienceBiological AssayBiological MarkersBiologyBrainCD4 Positive T LymphocytesCaringCause of DeathCerebrospinal FluidCessation of lifeChromosomesClinicalClinical ResearchCollaborationsCommunicable DiseasesComplexCryptococcal MeningitisCryptococcosisCryptococcusDevelopmentDiagnosticDiagnostic testsDiseaseExhibitsFailureFoundationsFundingGenesGeneticGenetic VariationGenomicsGenotypeGoalsHelper-Inducer T-LymphocyteHospitalizationHumanImmuneImmune responseImmunityImmunologic MarkersImmunologicsImmunologyImpairmentInfectionInflammatoryInfrastructureInterleukin-2LaboratoriesMediatingMedicalMeningitisMinnesotaMolecularMorbidity - disease rateMycosesNeurocognitive DeficitNeurologicNeurological outcomeOutcomePatient IsolationPatient-Focused OutcomesPatientsPhenotypePlasmaProcessResearchResearch PersonnelRisk FactorsScienceSerumSingle Nucleotide PolymorphismTechnologyTh1 CellsTranslatingTranslational ResearchTuberculosisUgandaUnited States National Institutes of HealthUniversitiesVariantVirulencechemokineclinical infrastructureclinical practiceclinical sequencingcytokinefungal geneticsgenome wide association studygenomic biomarkerhigh riskhigh risk populationin silicoknowledge basemonocytemortalitymortality riskmouse modelnervous system disorderneutrophilnovelpolarized cellprogramspublic health relevanceresearch studyresponseroutine caretraittranslational studytreatment strategy
项目摘要
Abstract
Cryptococcal meningitis (CM) is among the leading causes of death in AIDS-related opportunistic
infections and causes 15% of AIDS-related mortality globally. In Uganda, CM accounts for 60% of adult
meningitis in hospitalized patients. Even with treatment, the current mortality rate for CM is 65%, with
surviving patients often exhibiting neurological impairment. This poor survival is due to a complex
interaction between 1) failure to control fungal replication and 2) deleterious host immune response. To
reduce CM deaths, we must simultaneously mitigate Cryptococcus virulence while rebalancing
detrimental host responses towards protective immunity. The long-term objective of our research team
is to identify novel treatment strategies for CM that reduce morbidity and mortality associated with this
devastating disease. Our University of Minnesota, Mbarara University of Science and Technology, and
Makerere University research team has collaborated on CM clinical studies since 2009 – including three
NIH-funded trials. While similar clinical infrastructures are now present throughout Africa, there is still
limited ability to perform associated basic and translational research related to CM. Thus, we will
continue to build the infrastructure, knowledge base, and human capacity among African investigators
to perform basic research in genomics and immunology that is translatable to clinical practice.
Our research group has made two key discoveries that influence patient mortality with CM: a) an
immune signature associated with patient mortality, and b) that Cryptococcus genotype affects both
patient mortality and immune response. Specifically, our preliminary genome-wide association studies
(GWAS) identified 38 Cryptococcus genes associated with immune response and patient mortality in
closely related Ugandan CM patient isolates. Thus, the scientific objective for this proposal is to define
the impact of these Cryptococcus biomarkers on the immune response, and validate a subset of the
biomarkers in a mouse model of cryptococcosis. Two specific aims will accomplish this goal. In the first
aim, we will identify genomic differences and biomarkers in Cryptococcus isolates that influence patient
mortality and neurocognitive deficits after CM that encompass the genetic diversity present in Uganda.
We will then analyze associations between these genetic differences and patient immune responses in
the second aim to define both fungal genetic and human immune biomarkers that can be used in clinical
practice as the first step towards development of a diagnostic bioassay. Taken together, these
translational studies will define the molecular processes underlying CM and translate this information
(i.e. biomarkers) into novel clinical assays to identify high-risk individuals for acute mortality or
neurological impairment who would benefit from tailored medical care.
抽象的
隐球菌性脑膜炎 (CM) 是艾滋病相关机会性死亡的主要原因之一
感染并导致全球 15% 的艾滋病相关死亡。在乌干达,CM 占成人的 60%
住院患者的脑膜炎。即使进行治疗,目前 CM 的死亡率仍为 65%,
幸存的患者经常表现出神经功能障碍。这种不良的生存是由于复杂的
1) 未能控制真菌复制和 2) 有害的宿主免疫反应之间的相互作用。到
减少 CM 死亡,我们必须在重新平衡的同时减轻隐球菌毒力
宿主对保护性免疫的有害反应。我们研究团队的长期目标
的目的是确定新的 CM 治疗策略,以降低与此相关的发病率和死亡率
毁灭性的疾病。我们的明尼苏达大学、姆巴拉拉科技大学,以及
麦克雷雷大学研究团队自 2009 年以来一直在 CM 临床研究方面进行合作,其中包括三项
NIH 资助的试验。虽然类似的临床基础设施现在遍布非洲,但仍然存在
进行与 CM 相关的基础和转化研究的能力有限。这样,我们将
继续建设非洲调查人员的基础设施、知识库和人员能力
进行可转化为临床实践的基因组学和免疫学基础研究。
我们的研究小组取得了两项影响 CM 患者死亡率的关键发现:a)
免疫特征与患者死亡率相关,b) 隐球菌基因型影响两者
患者死亡率和免疫反应。具体来说,我们初步的全基因组关联研究
(GWAS) 鉴定了 38 个与免疫反应和患者死亡率相关的隐球菌基因
密切相关的乌干达 CM 患者分离株。因此,该提案的科学目标是定义
这些隐球菌生物标志物对免疫反应的影响,并验证了其中的一个子集
隐球菌病小鼠模型中的生物标志物。两个具体目标将实现这一目标。在第一个
目标,我们将确定影响患者的隐球菌分离株的基因组差异和生物标志物
CM 后的死亡率和神经认知缺陷涵盖了乌干达存在的遗传多样性。
然后我们将分析这些遗传差异与患者免疫反应之间的关联
第二个目标是定义可用于临床的真菌遗传和人类免疫生物标志物
实践是开发诊断生物测定的第一步。综合起来,这些
转化研究将定义 CM 的分子过程并转化这些信息
(即生物标志物)进入新的临床测定中,以识别急性死亡的高风险个体或
神经障碍患者将受益于量身定制的医疗护理。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Lack of Association between Fluconazole Susceptibility and ERG11 Nucleotide Polymorphisms in Cryptococcus neoformans Clinical Isolates from Uganda.
- DOI:10.3390/jof8050508
- 发表时间:2022-05-15
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Cryptococcus neoformans Genotypic Diversity and Disease Outcome among HIV Patients in Africa.
- DOI:10.3390/jof8070734
- 发表时间:2022-07-15
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
MinION Whole-Genome Sequencing in Resource-Limited Settings: Challenges and Opportunities.
- DOI:10.1007/s40588-022-00183-1
- 发表时间:2022
- 期刊:
- 影响因子:5.2
- 作者:Wasswa, Fredrickson B.;Kassaza, Kennedy;Nielsen, Kirsten;Bazira, Joel
- 通讯作者:Bazira, Joel
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joel Bazira其他文献
Joel Bazira的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joel Bazira', 18)}}的其他基金
Genomic Research Capacity Building for Cryptococcosis Translational Studies
隐球菌病转化研究的基因组研究能力建设
- 批准号:
10231242 - 财政年份:2020
- 资助金额:
$ 55.26万 - 项目类别:
Genomic Research Capacity Building for Cryptococcosis Translational Studies
隐球菌病转化研究的基因组研究能力建设
- 批准号:
10459388 - 财政年份:2020
- 资助金额:
$ 55.26万 - 项目类别:
Genomic Research Capacity Building for Cryptococcosis Translational Studies
隐球菌病转化研究的基因组研究能力建设
- 批准号:
10053575 - 财政年份:2020
- 资助金额:
$ 55.26万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 55.26万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 55.26万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 55.26万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 55.26万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 55.26万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 55.26万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 55.26万 - 项目类别: